The latest headlines across every section, pulled from official and open-access sources.
The issue is not only functional. It is experiential. Many women do not need more scores. They need continuity, context, and support that feels companionable rather than corrective. The post Women’s Health Is Not a Wearable Feature — It’s an Operating System Problem appeared first on MedCity News .
Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots are part of an overall FDA effort to make demographic data more available and transparent.
In this week’s View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes.
Digital health solutions are booming, but a critical roadblock stands in the way: the lack of a common quality framework. Purchasers seek greater transparency from vendors regarding how their solutions engage members and improve health outcomes, while vendors need better data on the members they serve to provide more effective support. NCQA is launching a […] The post NCQA Launches Digital Health Engagement Accreditation Program appeared first on NCQA .
The in-depth, constantly-changing birds-eye view of disease that computational models provide is an essential next step in linking our ever-expanding clinical knowledge and data with drug development. The post From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies appeared first on MedCity News .
Here’s how alternative care pathways are changing the way we think about patient discharge and how to create effective and safe disposition options from both emergency department (ED) and inpatient settings. The post Care Without Walls: Scaling Alternatives to Skilled Nursing Facilities appeared first on MedCity News .
This report presents data from the National Enhanced Legionnaires' Disease Surveillance Scheme (NELSS), covering all confirmed cases of Legionellosis among residents of England and Wales with symptom onset between January 1 and December 31, 2025. The report's purpose is to analyse confirmed cases, which meet specific clinical and laboratory criteria, and compare findings against data from previous years. Data is drawn from national surveillance scheme reporting forms and population estimates are based on the ONS census. The report will provide an epidemiological summary, analyse overall trends…
Landmark patient safety initiative, Martha's Rule, rolled out to all maternity settings after review found serious and sustained failures.
This register contains all websites that are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) to sell medicines online, in Northern Ireland.
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Immunomedics Inc
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Immunomedics Inc
Efficacy supplement (new or revised indication). solution, subcutaneous. Sponsor: Ionis Pharms Inc
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Merck Sharp Dohme
Efficacy supplement (new or revised indication). capsule, oral. Sponsor: Pfizer
Efficacy supplement (new or revised indication). tablet, oral. Sponsor: Pfizer
Efficacy supplement (new or revised indication). solution, intravenous. Sponsor: Merck Sharp Dohme
Defective container:may contain bottles with incomplete seals — Keystone Industries · Class II · Ongoing · 150 units
CGMP Deviations; deficiencies observed during FDA inspection — Dabur India Limited · Class II · Ongoing · 4,944 tubes
Defective container:may contain bottles with incomplete seals — Keystone Industries · Class II · Ongoing · 450 units
CGMP Deviations; deficiencies observed during FDA inspection — Dabur India Limited · Class II · Ongoing · 84 tubes
CGMP Deviations; deficiencies observed during FDA inspection — Dabur India Limited · Class II · Ongoing · 3006 tubes
CGMP Deviations; deficiencies observed during FDA inspection — Dabur India Limited · Class II · Ongoing · 2503 tubes
CGMP Deviations; deficiencies observed during FDA inspection — Dabur India Limited · Class II · Ongoing · 1185 tubes
Subpotent Drug — IntegraDose Compounding Services LLC · Class II · Ongoing · 287 units